100000 cases of aidi injection post-market safety evaluation to the real world research again

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-16010277

Enrollment

Unknown

Registered

2016-12-28

Start date

2017-01-02

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

Case series:Aidi injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cell or tissue pathology diagnosis for malignant tumor,and Hospitalized patients using eddy injection.

Exclusion criteria

Exclusion criteria: No

Design outcomes

Primary

Measure	Time frame
safety;	—

Countries

China

Contacts

Public ContactWei Zhou

Guizhou Yibai Pharmaceutical Co., Ltd.

876336183@qq.com+86 13918358283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026